An interventional study of Triclosan-Coated Polyglactin 910 Suture and Conventional Polyglactin 910 Suture in Nasal Septal Deviation, Surgical Wound Healing and Surgical Site Infection, sponsored by Sakarya University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Sakarya University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Surgical Wound Infection with a site in Turkey — 10 open to participants now, 14 under way, none of them phase 3. Surgical Wound Infection · Turkey.
Among the 31 studies in Surgical Wound Infection with a site in Turkey, this one is the 7th largest by enrollment of the 26 interventional ones that give a count, is one of 5 that started in 2025, is one of 24 with no phase, and was the 31st registered.
746 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.
Browse Surgical Wound Infection studies →10 of the 31 studies in Surgical Wound Infection with a site in Turkey are open now. Recruiting first, the newest first:
Mahmut Yassa · Sites in Turkey
Ages 18+ · Women only
Başakşehir Çam & Sakura City Hospital · Sites in Turkey
Ages 17–60 · Women only
Bahattin Kemah · Sites in Turkey
Ages 30+
Necmi Kadıoğlu Hospital · Sites in Turkey
Ages 5–18
Malatya Turgut Ozal University · Sites in Turkey
Ages 18–65
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 84 Surgical Wound Infection studies recruiting now, 60 (71%) set no upper age limit and 16 (19%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 5 started in 2025.
This study's enrollment of 142 is below the median of 200 across 582 interventional studies indexed under Surgical Wound Infection.
Median enrollment 89 across the 26 interventional studies, 102 across the 5 observational. Of the 15 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 31 has an industry lead sponsor. The 10 most frequent:
Sakarya University is the lead sponsor of 190 studies on the registry; 53 are open to participants now.
Sakarya University has 2 studies filed under Surgical Wound Infection — fewer than ten, so there is no comparison to draw.
1 of the studies in Surgical Wound Infection with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07751692Fatih Sultan Mehmet Training and Research HospitalGNRI and Rectus Femoris Muscle Thickness in Older Patients Undergoing Hip Fracture Surgery | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies in Surgical Wound Infection with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn whether an antibacterial (triclosan-coated) suture improves healing after septoplasty in adults, compared with a conventional suture of the same material. The main questions it aims to answer are:
Researchers compared triclosan-coated polyglactin 910 sutures (Coated VICRYL Plus Antibacterial) with uncoated polyglactin 910 sutures (Coated VICRYL) to see whether the antibacterial coating affects healing, infection, pain and comfort.
Participants:
Design and setting: Single-centre, prospective, randomized, controlled, parallel-group trial conducted in the Department of Otorhinolaryngology, Sakarya University Training and Research Hospital (Sakarya, Türkiye) between 1 June 2025 and 31 December 2025. The protocol was approved by the local ethics committee (decision no. 266, 21 May 2025), and written informed consent was obtained from all participants.
Allocation and masking: Participants were allocated in a 1:1 ratio to the antibacterial suture group or the conventional suture group by block randomization. Participants were not informed of the suture type. Postoperative endoscopic assessments, scoring and structured interviews on days 7 and 21 were performed by an investigator masked to group allocation.
Intervention: Septoplasty was performed through a hemitransfixion incision with elevation of mucoperichondrial and, where necessary, mucoperiosteal flaps. Deviated cartilage and bone were corrected while preserving dorsal and caudal support (L-strut). After haemostasis, the flaps were reapproximated and transseptal sutures were placed. The incision was closed with the suture allocated to the participant: 4-0 Coated VICRYL Plus Antibacterial (triclosan-coated polyglactin 910) or 4-0 Coated VICRYL (polyglactin 910), both manufactured by Ethicon. Inferior turbinate radiofrequency reduction and/or outfracture were performed when clinically indicated. All other perioperative care, including routine antibiotic prophylaxis, was the same in both groups.
Assessments: On postoperative days 7 and 21, mucosal healing, edema, hematoma, suture-site reaction, suture material status and clinical signs of infection were assessed by nasal endoscopy and anterior rhinoscopy. Pain (visual analogue scale), nasal obstruction (validated Turkish version of the Nasal Obstruction Symptom Evaluation scale) and comfort items (relief of nasal obstruction, intranasal pressure sensation, return to daily activities and overall comfort) were collected in a structured face-to-face interview.
Registration note: This trial was registered retrospectively, after completion of enrolment and follow-up and before submission of the results for publication. The ethics-approved protocol did not designate a single primary endpoint. The primary outcome measures in this record correspond to the main objectives stated in the protocol (wound healing, infection, pain and comfort), and all between-group comparisons are reported as exploratory.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Septoplasty with closure of the hemitransfixion incision using 4-0 triclosan-coated polyglactin 910 suture (Coated VICRYL Plus Antibacterial).
Device: Triclosan-Coated Polyglactin 910 Suture
Septoplasty with closure of the hemitransfixion incision using 4-0 uncoated polyglactin 910 suture of the same size (Coated VICRYL).
Device: Conventional Polyglactin 910 Suture
4-0 braided, absorbable polyglactin 910 suture coated with triclosan, used to close the septal incision at the end of septoplasty. All other surgical steps and perioperative care were identical to the comparator arm.
4-0 braided, absorbable polyglactin 910 suture without antibacterial coating, of the same size, used in the same way to close the septal incision.
Mucosal Healing Grade at the Septal Incision
Healing of the septal incision and mucosal flaps assessed by nasal endoscopy and anterior rhinoscopy by an assessor masked to group allocation, graded as 1 = normal, 2 = delayed, 3 = inflamed healing. Lower grades indicate better healing.
Time frame: Postoperative day 7 and postoperative day 21
Number of Participants With Clinical Signs of Surgical Site Infection
Presence of local edema, erythema, purulent or serous discharge, or tissue tenderness at the operated septum, recorded as present or absent by an assessor masked to group allocation.
Time frame: Postoperative day 7 and postoperative day 21
Postoperative Pain Intensity on a Visual Analogue Scale (VAS)
Pain rated by the participant on a 0-10 visual analogue scale (0 = no pain, 10 = unbearable pain). Higher scores indicate worse pain.
Time frame: Postoperative day 7 and postoperative day 21
Overall Postoperative Comfort Score
Overall comfort rated by the participant on a 5-point Likert scale (range 1-5) in a structured face-to-face interview. Higher scores indicate greater comfort.
Time frame: Postoperative day 7 and postoperative day 21
Edema Score at the Surgical Site
Edema at the septal incision graded by nasal endoscopy by a masked assessor as 0 = none, 1 = mild, 2 = moderate, 3 = severe. Higher scores indicate more edema.
Time frame: Postoperative day 7 and postoperative day 21
Number of Participants With Septal Hematoma
Presence of septal hematoma on endoscopic examination, recorded as present or absent.
Time frame: Postoperative day 7 and postoperative day 21
Suture-Site Reaction
Reaction at the suture line on endoscopic examination, categorized as none, erythema, granulation tissue or wound dehiscence (number of participants in each category).
Time frame: Postoperative day 7 and postoperative day 21
Suture Material Status
Status of the suture material on endoscopic examination, categorized as in situ, broken or dislodged (number of participants in each category).
Time frame: Postoperative day 7 and postoperative day 21
Nasal Obstruction Symptom Evaluation (NOSE) Score
Validated Turkish version of the NOSE scale: five items scored 0-4, raw total 0-20. Higher scores indicate worse nasal obstruction.
Time frame: Postoperative day 7 and postoperative day 21
Relief of Nasal Obstruction Score
Rated by the participant on a 5-point Likert scale (range 1-5). Higher scores indicate greater relief of nasal obstruction.
Time frame: Postoperative day 7 and postoperative day 21
Intranasal Pressure Sensation Score
Rated by the participant on a 5-point Likert scale (range 1-5). Higher scores indicate a more favourable status (less intranasal pressure sensation).
Time frame: Postoperative day 7 and postoperative day 21
Return to Activities of Daily Living Score
Rated by the participant on a 5-point Likert scale (range 1-5). Higher scores indicate an easier return to daily activities.
Time frame: Postoperative day 7 and postoperative day 21
Plan to share: Yes — De-identified individual participant data underlying the published results will be made available upon reasonable request to the corresponding author.
Supporting information: Study protocol
Time frame: From publication of the main results, for 5 years.
Access criteria: Requests are reviewed by the principal investigator. Data are shared after approval of a methodologically sound proposal and signature of a data-sharing agreement, in accordance with Turkish personal data protection legislation.
No publications or documents are linked to this record.
Ran from Jun 2025 to primary completion in Dec 2025, 6 months.
Of 201 non-industry interventional studies with no phase under Surgical Wound Infection, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's 6 months is below that.
Counting every sponsor, half of 208 studies reached it within 24 months; a quarter within 12 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.